scholarly article | Q13442814 |
P2093 | author name string | Baohui Han | |
Jie Shen | |||
Chunlei Shi | |||
Aiqin Gu | |||
Liwen Xiong | |||
P2860 | cites work | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. | Q30650378 | ||
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer | Q35017984 | ||
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. | Q35610264 | ||
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs | Q36692592 | ||
Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer | Q37756959 | ||
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study | Q42673292 | ||
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. | Q43056663 | ||
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). | Q50782266 | ||
Epidemiology of Lung Cancer* | Q54195851 | ||
Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time | Q81219117 | ||
P433 | issue | 6 | |
P407 | language of work or name | Chinese | Q7850 |
P921 | main subject | adenocarcinoma | Q356033 |
erlotinib | Q418369 | ||
P304 | page(s) | 529-533 | |
P577 | publication date | 2011-06-01 | |
P1433 | published in | Chinese Journal of Lung Cancer | Q26842043 |
P1476 | title | [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy]. | |
P478 | volume | 14 |